---
title: "J.P. Morgan Reaffirms Their Buy Rating on AstraZeneca (AZN)"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/292602044.md"
description: "J.P. Morgan analyst Richard Vosser reaffirmed a Buy rating on AstraZeneca (AZN) with a £160 price target, citing his strong track record. This follows a recent Buy from Jefferies, while HSBC simultaneously downgraded the stock to Hold."
datetime: "2026-07-14T09:45:16.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/292602044.md)
  - [en](https://longbridge.com/en/news/292602044.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/292602044.md)
---

# J.P. Morgan Reaffirms Their Buy Rating on AstraZeneca (AZN)

In a report released today, Richard Vosser from J.P. Morgan maintained a Buy rating on AstraZeneca, with a price target of £160.00.

### TipRanks Welcomes a New ETF – NYSE:RANK

-   TipRanks has entered a new arena in the investing world, powering the index of an ETF based on its unique data now trading under the ticker RANK on the NYSE.
-   RANK tracks the performance of the TipRanks US Momentum Analysts Index, a rules-based index of 50 large U.S. companies.

According to TipRanks, Vosser is a 3-star analyst with an average return of 2.2% and a 49.25% success rate.

In addition to J.P. Morgan, AstraZeneca also received a Buy from Jefferies’s Michael Leuchten in a report issued yesterday. However, on the same day, HSBC downgraded AstraZeneca (LSE: AZN) to a Hold.

### Related Stocks

- [AZN.US](https://longbridge.com/en/quote/AZN.US.md)
- [AZN.UK](https://longbridge.com/en/quote/AZN.UK.md)
- [JEF.US](https://longbridge.com/en/quote/JEF.US.md)
- [HSBC.US](https://longbridge.com/en/quote/HSBC.US.md)
- [HSBA.UK](https://longbridge.com/en/quote/HSBA.UK.md)
- [HSBH.US](https://longbridge.com/en/quote/HSBH.US.md)
- [JPM.US](https://longbridge.com/en/quote/JPM.US.md)
- [RANK.US](https://longbridge.com/en/quote/RANK.US.md)
- [00005.HK](https://longbridge.com/en/quote/00005.HK.md)
- [JPM-M.US](https://longbridge.com/en/quote/JPM-M.US.md)
- [JPM-C.US](https://longbridge.com/en/quote/JPM-C.US.md)
- [JPM-D.US](https://longbridge.com/en/quote/JPM-D.US.md)
- [JPM-L.US](https://longbridge.com/en/quote/JPM-L.US.md)
- [8634.JP](https://longbridge.com/en/quote/8634.JP.md)
- [JPM-K.US](https://longbridge.com/en/quote/JPM-K.US.md)
- [JPM-J.US](https://longbridge.com/en/quote/JPM-J.US.md)
- [DTIW.SG](https://longbridge.com/en/quote/DTIW.SG.md)

## Related News & Research

- [AstraZeneca’s Etcamah-CDK4/6 combo wins EU approval for 1st-line advanced ER-positive breast cancer](https://longbridge.com/en/news/293566585.md)
- [J.P. Morgan Sticks to Their Buy Rating for AstraZeneca (AZN)](https://longbridge.com/en/news/293338532.md)
- [AstraZeneca Reports Q2 Earnings Next Week. What Investors Should Expect.](https://longbridge.com/en/news/293758772.md)
- [Astrazeneca Plc $AZN Shares Sold by Compound Planning Inc.](https://longbridge.com/en/news/293816614.md)
- [AstraZeneca asthma inhaler Trixeo wins positive EU CHMP opinion for approval](https://longbridge.com/en/news/293742333.md)